Factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) Mutations in Yemeni Subjects Tested for Thrombophilia

Mohammed Ahamed Hajar; Sami Sultan Ahmed; Basem Mohammed Abdulfattah

doi:doi:10.11648/j.ajhr.20251303.11

Review Article |

| Peer-Reviewed

Factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) Mutations in Yemeni Subjects Tested for Thrombophilia

Mohammed Ahamed Hajar^*

, Sami Sultan Ahmed

, Basem Mohammed Abdulfattah

Published in American Journal of Health Research (Volume 13, Issue 3)

Received: 8 January 2025 Accepted: 12 March 2025 Published: 24 May 2025

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The Factor V Leiden (G1691A), Prothrombin gene (G20210A) and MTHFR (C677T) mutations are the significant biomarkers for evaluation of tendency for venous thrombosis. The objective of our study was to assess the frequency of factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) variants in Yemeni subjects tested for thrombophilia. Methods: Our study included 441 thrombophilia subjects (138 subjects for FVL (G1691A) mutation, 164 subjects for PT (G20210A) mutation and 139 for MTHFR (C677T) mutation) who were genotyped by method of SNP Genotyping Assay (FVL, PT and MTHFR variants Real Time PCR Kits), and the allele frequencies of factor V Leiden (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations were calculated. The laboratory data of patients tested were reviewed and analyzed in the Aulaqi specialized medical laboratories. Results: Factor V Leiden (G1691A) mutation was present in 10% of all subjects (heterozygotes: 10%, homozygotes mutant: 0%). Prothrombin (G20210A) mutation was found in 8.5% of subjects (heterozygotes: 7.3%, homozygotes mutant: 1.2%) and MTHFR (C677T) mutation in 39.5% of subjects (heterozygotes: 34.5%, homozygotes mutant: 5%). Conclusion: This study reports high prevalence of FVL (G1691A), PT (G20210A) and MTHFR (C677T) mutations among subjects with thrombophilia. Consequently, genotyping assay for of the three thrombotic gene mutations have a priority in the evaluation of subjects with thrombophilia, as well as in the screening for additional clinical conditions correlated with an elevated risk of thrombosis in Sana'a city-Yemen.

Published in	American Journal of Health Research (Volume 13, Issue 3)
DOI	10.11648/j.ajhr.20251303.11
Page(s)	131-138
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2025. Published by Science Publishing Group

Keywords

Thrombophilia, Venous Thromboembolism, Factor V Leiden (G1691A), Prothrombin (G20210A), MTHFR (C677T), Mutation, Yemen

References

[1]	Purcell, A., M. Clarke, and I. Maidment, Venous thromboembolism prophylaxis in mental health in-patient services: a qualitative study. International Journal of Clinical Pharmacy, 2018. 40(3): p. 543-549. https://doi.org/10.1007/s11096-018-0599-7
[2]	Wade, R., F. Paton, and N. Woolacott, Systematic review of patient preference and adherence to the correct use of graduated compression stockings to prevent deep vein thrombosis in surgical patients. Journal of advanced nursing, 2017. 73(2): p. 336-348. https://doi.org/10.1111/jan.13148
[3]	Dicks, A. B., et al., A comprehensive review of risk factors and thrombophilia evaluation in venous thromboembolism. Journal of Clinical Medicine, 2024. 13(2): p. 362. https://doi.org/10.3390/jcm13020362
[4]	van Ommen, C. H. and U. Nowak-Göttl, Inherited thrombophilia in pediatric venous thromboembolic disease: why and who to test. Frontiers in pediatrics, 2017. 5: p. 50. https://doi.org/10.3389/fped.2017.00050
[5]	Kenet, G., et al., Risk factors for symptomatic venous and arterial thromboembolism in newborns, children and adolescents–what did we learn within the last 20 years? Blood Cells, Molecules, and Diseases, 2017. 67: p. 18-22. https://doi.org/10.1016/j.bcmd.2016.12.003
[6]	McLendon, K., A. Goyal, and M. Attia, Deep venous thrombosis risk factors. 2017. https://www.ncbi.nlm.nih.gov/books/NBK470215/
[7]	Ghorbani, M., et al., Comparison of two methods for factor five Leiden detection in patients with thromboembolism. Biomed Res, 2018. 29(8): p. 1685-8. https://doi.org/10.4066/biomedicalresearch.29-17-2646
[8]	Shafia, S., et al., High prevalence of factor V Leiden and prothrombin G20101A mutations in Kashmiri patients with venous thromboembolism. Gene, 2018. 654: p. 1-9. https://doi.org/10.1016/j.gene.2018.02.031
[9]	Zöller, B., et al., Genetic risk factors for venous thromboembolism. Expert Review of Hematology, 2020. 13(9): p. 971-981. https://doi.org/10.1080/17474086.2020.1804354
[10]	Hamidpour, M., et al., A study of the natural coagulating inhibitors polymorphism in Iranian patients with the vine thrombosis. Int J, 2015. 2(2): p. 47-53. http://pubs.sciepub.com/ijhd/2/2/5
[11]	Assaf, N., et al., Prevalence of thrombophilia-associated mutations and their clinical significance in a large cohort of Lebanese patients. Meta Gene, 2021. 29: p. 100936. https://doi.org/10.1016/j.mgene.2021.100936
[12]	Raptopoulou, A., et al., Large-scale screening for factor V Leiden (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations in Greek population. Health Science Reports, 2022. 5(4): p. e457. https://doi.org/10.1002/hsr2.457
[13]	Dajani, R., et al., Prevalence of coagulation factor II G20210A and factor V G1691A Leiden polymorphisms in Chechans, a genetically isolated population in Jordan. Molecular biology reports, 2012. 39: p. 9133-9138. https://doi.org/10.1007/s11033-012-1785-7
[14]	Madkhaly, F., et al., Prevalence of positive factor V Leiden and prothrombin mutations in samples tested for thrombophilia in Saudi Arabia. American Journal of Blood Research, 2021. 11(3): p. 255. https://pmc.ncbi.nlm.nih.gov/articles/PMC8303010/
[15]	Bourouba, R., et al., The prevalence of methylenetetrahydrofolate reductase 677 CT, factor V 1691 GA, and prothrombin 20210 GA mutations in healthy populations in Setif, Algeria. Clinical and Applied Thrombosis/Hemostasis, 2009. 15(5): p. 529-534. https://doi.org/10.1177/1076029608319944
[16]	Kreidy, R., Factor V-Leiden mutation: a common risk factor for venous thrombosis among Lebanese patients. Thrombosis, 2012. 2012(1): p. 380681. https://doi.org/10.1155/2012/380681
[17]	Butenas, S., C. van’t Veer, and K. G. Mann, “Normal” Thrombin Generation: Presented in part at the XVIth Congress of the International Society on Thrombosis and Haemostasis, June 6-12, 1997, Florence, Italy (abstr PS-1653), at the 15th International Congress on Thrombosis, October 16-21, 1998, Antalya, Turkey (abstr 234), and at the 40th Annual Meeting of the American Society of Hematology, December 4-8, 1998, Miami Beach, FL (abstr 151). Blood, The Journal of the American Society of Hematology, 1999. 94(7): p. 2169-2178. https://doi.org/10.1182/blood.V94.7.2169.419k22_2169_2178
[18]	Kraaijenhagen, R. A., et al., High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thrombosis and haemostasis, 2000. 83(01): p. 5-9. https://doi.org/10.1055%2Fs-0037-1613747
[19]	Emmerich, J., et al., Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism. Thrombosis and haemostasis, 2001. 86(09): p. 809-816. https://doi.org/10.1055/s-0037-1616136
[20]	Rosendaal, F. R., et al., Geographic distribution of the 20210 G to A prothrombin variant. Thrombosis and haemostasis, 1998. 79(04): p. 706-708. https://doi.org/10.1055%2Fs-0037-1615049
[21]	Ni, J., et al., Association between the MTHFR C677T polymorphism, blood folate and vitamin B12 deficiency, and elevated serum total homocysteine in healthy individuals in Yunnan Province, China. Journal of the Chinese Medical Association, 2017. 80(3): p. 147-153. https://doi.org/10.1016/j.jcma.2016.07.005
[22]	dos Santos Nunes, M. K., et al., Hypermethylation in the promoter of the MTHFR gene is associated with diabetic complications and biochemical indicators. Diabetology & metabolic syndrome, 2017. 9: p. 1-9. https://doi.org/10.1186/s13098-017-0284-3
[23]	Anderson Jr, F. A. and F. A. Spencer, Risk factors for venous thromboembolism. Circulation, 2003. 107(23_suppl_1): p. I-9-I-16. https://doi.org/10.1161/01.CIR.0000078469.07362.E6
[24]	Wilcken, B., et al., Geographical and ethnic variation of the 677C> T allele of 5, 10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. Journal of medical genetics, 2003. 40(8): p. 619-625. https://doi.org/10.1136/jmg.40.8.619
[25]	Koksal, V., I. Baris, and O. Etlik, Primer-engineered multiplex PCR–RFLP for detection of MTHFR C677T, prothrombin G20210A and factor V Leiden mutations. Experimental and molecular pathology, 2007. 83(1): p. 1-3. https://doi.org/10.1016/j.yexmp.2006.12.006
[26]	Bezgin, T., et al., Thrombophilic gene mutations in relation to different manifestations of venous thromboembolism: a single tertiary center study. Clinical and Applied Thrombosis/Hemostasis, 2018. 24(1): p. 100-106. https://doi.org/10.1177/1076029616672585
[27]	Cohen, A. T., et al., Venous thromboembolism (VTE) in Europe. Thrombosis and haemostasis, 2007. 98(10): p. 756-764. http://doi.org/10.1160/th07-03-0212
[28]	Rees, D. C., M. Cox, and J. B. Clegg, World distribution of factor V Leiden. Lancet (London, England), 1995. 346(8983): p. 1133-1134. https://doi.org/10.1016/s0140-6736(95)91803-5
[29]	Stone, J., et al., Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovascular diagnosis and therapy, 2017. 7(Suppl 3): p. S276. https://doi.org/10.21037/cdt.2017.09.01
[30]	Kujovich, J. L., Factor v Leiden thrombophilia. Genetics in medicine, 2011. 13(1): p. 1-16. https://doi.org/10.1097/GIM.0b013e3181faa0f2
[31]	Thorelli, E., R. J. Kaufman, and B. r. Dahlbäck, Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood, The Journal of the American Society of Hematology, 1999. 93(8): p. 2552-2558. https://doi.org/10.1182/blood.V93.8.2552
[32]	Albagoush, S. A., et al., Factor V leiden mutation, in StatPearls [Internet]. 2023, StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK534802/
[33]	Ravin, A. J., et al., The factor V Leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients. Obstetrics & Gynecology, 2002. 100(6): p. 1285-1289. https://doi.org/10.1016/S0029-7844(02)02320-7
[34]	Lucotte, G. and G. Mercier, Population genetics of factor V Leiden in Europe. Blood Cells, Molecules, and Diseases, 2001. 27(2): p. 362-367. https://doi.org/10.1006/bcmd.2001.0388
[35]	Salmanpoor, Z., et al., Investigating the frequency of resistance to activated protein C and protein S, C and antithrombin deficiencies in patients with deep vein thrombosis referred to the Iranian blood transfusion organization. Journal of Advances in Medical and Biomedical Research, 2017. 25(112): p. 21-29. http://journal.zums.ac.ir/article-1-4587-en.html
[36]	Poort, S. R., et al., A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. 1996. https://doi.org/10.1182/blood.V88.10.3698.bloodjournal88103698
[37]	Kyrle, P. A., et al., High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. New England Journal of Medicine, 2000. 343(7): p. 457-462. https://doi.org/10.1056/NEJM200008173430702
[38]	Kim, R. J. and R. C. Becker, Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. American heart journal, 2003. 146(6): p. 948-957. https://doi.org/10.1016/S0002-8703(03)00519-2
[39]	Wawrusiewicz-Kurylonek, N., A. J. Krętowski, and R. Posmyk, Frequency of thrombophilia associated genes variants: population-based study. BMC Medical Genetics, 2020. 21: p. 1-5. https://doi.org/10.1186/s12881-020-01136-5
[40]	Frosst, P., et al., A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature genetics, 1995. 10(1): p. 111-113. https://doi.org/10.1038/ng0595-111
[41]	den Heijer, M., et al., Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? The Lancet, 1995. 345(8954): p. 882-885. https://doi.org/10.1016/S0140-6736(95)90008-X
[42]	Guéant-Rodriguez, R.-M., et al., Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: a comparative study in Mexican, West African, and European populations. The American journal of clinical nutrition, 2006. 83(3): p. 701-707. https://doi.org/10.1093/ajcn.83.3.701
[43]	Fujimura, H., et al., Common C677T polymorphism in the methylenetetrahydrofolate reductase gene increases the risk for deep vein thrombosis in patients with predisposition of thrombophilia. Thrombosis research, 2000. 98(1): p. 1-8. https://doi.org/10.1016/S0049-3848(99)00231-5
[44]	Khan, M. A., et al., A High Incidence of Patients with MTHFR (methylenetetrahydrofolate reductase) Gene Mutations Noted in An Appalachian Population Seen for Thrombophilia at the West Virginia University Outpatient Hematology Clinic, 2006–2008. Blood, 2008. 112(11): p. 4500. https://doi.org/10.1182/blood.V112.11.4500.4500
[45]	Saour, J. N., M. M. Shoukri, and L. A. Mammo, The Saudi Thrombosis and Familial Thrombophilia Registry. Design, rational, and preliminary results. Saudi medical journal, 2009. 30(10): p. 1286-1290. https://smj.org.sa/content/smj/30/10/1286.full.pdf
[46]	Ekim, M., H. Ekim, and Y. Yılmaz, The prevalence of Factor V Leiden, prothrombin G20210A, MTHFR C677T and MTHFR A1298C mutations in healthy Turkish population. Hippokratia, 2015. 19(4): p. 309. https://pmc.ncbi.nlm.nih.gov/articles/PMC5033140/pdf/hippokratia-19-309.pdf
[47]	Egin, M. E., et al., Investigation of the Frequency of Thrombophilic Gene Mutations in Patients with Venous Thromboembolism in Eastern Turkey. Genel Tıp Dergisi, 2023. 33(3): p. 268-273. https://doi.org/10.54005/geneltip.1196430
[48]	ŞAHİN, Ş., I. Benli, and L. AYDOĞAN, Distribution of prothrombin G20210A, factor V Leiden, and MTHFR C677T mutations in the middle Black Sea area (Tokat) of Turkey. Turkish Journal of Medical Sciences, 2012. 42(6): p. 1093-1097. https://doi.org/10.3906/sag-1107-51
[49]	Salem-Berrabah, O. B., et al., Thrombophilic polymorphisms–factor V Leiden G1691A, prothrombin G20210A and MTHFR C677T–in Tunisian patients with cerebral venous thrombosis. Journal of Clinical Neuroscience, 2012. 19(9): p. 1326-1327. https://doi.org/10.1016/j.jocn.2011.11.029
[50]	Hamidpour, M., et al., Factor V Leiden, MTHFR C677T and prothrombin gene mutation G20210A in Iranian patients with venous thrombosis. Iranian Journal of Blood and Cancer, 2019. 11(3): p. 91-95. http://ijbc.ir/article-1-888-en.html
[51]	Alfirevic, Z., et al., Frequency of factor II G20210A, factor V Leiden, MTHFR C677T and PAI-1 5G/4G polymorphism in patients with venous thromboembolism: Croatian case-control study. Biochemia Medica, 2010. 20(2): p. 229-235. https://doi.org/10.11613/BM.2010.028
[52]	Tug, E., et al., Frequency of genetic mutations associated with thromboembolism in the Western Black Sea Region. Internal Medicine, 2011. 50(1): p. 17-21. https://doi.org/10.2169/internalmedicine.50.4144
[53]	Jusić-Karić, A., et al., Frequency and association of 1691 (G> A) FVL, 20210 (G> A) PT and 677 (C> T) MTHFR with deep vein thrombosis in the population of Bosnia and Herzegovina. Balkan Journal of Medical Genetics, 2016. 19(1): p. 43-50. https://doi.org/10.1515/bjmg-2016-0006

Cite This Article

Plain Text BibTeX RIS

APA Style

Hajar, M. A., Ahmed, S. S., Abdulfattah, B. M. (2025). Factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) Mutations in Yemeni Subjects Tested for Thrombophilia. American Journal of Health Research, 13(3), 131-138. https://doi.org/10.11648/j.ajhr.20251303.11

Copy | Download

ACS Style

Hajar, M. A.; Ahmed, S. S.; Abdulfattah, B. M. Factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) Mutations in Yemeni Subjects Tested for Thrombophilia. Am. J. Health Res. 2025, 13(3), 131-138. doi: 10.11648/j.ajhr.20251303.11

Copy | Download

AMA Style

Hajar MA, Ahmed SS, Abdulfattah BM. Factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) Mutations in Yemeni Subjects Tested for Thrombophilia. Am J Health Res. 2025;13(3):131-138. doi: 10.11648/j.ajhr.20251303.11

Copy | Download

@article{10.11648/j.ajhr.20251303.11,
  author = {Mohammed Ahamed Hajar and Sami Sultan Ahmed and Basem Mohammed Abdulfattah},
  title = {Factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) Mutations in Yemeni Subjects Tested for Thrombophilia
},
  journal = {American Journal of Health Research},
  volume = {13},
  number = {3},
  pages = {131-138},
  doi = {10.11648/j.ajhr.20251303.11},
  url = {https://doi.org/10.11648/j.ajhr.20251303.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajhr.20251303.11},
  abstract = {The Factor V Leiden (G1691A), Prothrombin gene (G20210A) and MTHFR (C677T) mutations are the significant biomarkers for evaluation of tendency for venous thrombosis. The objective of our study was to assess the frequency of factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) variants in Yemeni subjects tested for thrombophilia. Methods: Our study included 441 thrombophilia subjects (138 subjects for FVL (G1691A) mutation, 164 subjects for PT (G20210A) mutation and 139 for MTHFR (C677T) mutation) who were genotyped by method of SNP Genotyping Assay (FVL, PT and MTHFR variants Real Time PCR Kits), and the allele frequencies of factor V Leiden (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations were calculated. The laboratory data of patients tested were reviewed and analyzed in the Aulaqi specialized medical laboratories. Results: Factor V Leiden (G1691A) mutation was present in 10% of all subjects (heterozygotes: 10%, homozygotes mutant: 0%). Prothrombin (G20210A) mutation was found in 8.5% of subjects (heterozygotes: 7.3%, homozygotes mutant: 1.2%) and MTHFR (C677T) mutation in 39.5% of subjects (heterozygotes: 34.5%, homozygotes mutant: 5%). Conclusion: This study reports high prevalence of FVL (G1691A), PT (G20210A) and MTHFR (C677T) mutations among subjects with thrombophilia. Consequently, genotyping assay for of the three thrombotic gene mutations have a priority in the evaluation of subjects with thrombophilia, as well as in the screening for additional clinical conditions correlated with an elevated risk of thrombosis in Sana'a city-Yemen.
},
 year = {2025}
}

Copy | Download

TY  - JOUR
T1  - Factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) Mutations in Yemeni Subjects Tested for Thrombophilia

AU  - Mohammed Ahamed Hajar
AU  - Sami Sultan Ahmed
AU  - Basem Mohammed Abdulfattah
Y1  - 2025/05/24
PY  - 2025
N1  - https://doi.org/10.11648/j.ajhr.20251303.11
DO  - 10.11648/j.ajhr.20251303.11
T2  - American Journal of Health Research
JF  - American Journal of Health Research
JO  - American Journal of Health Research
SP  - 131
EP  - 138
PB  - Science Publishing Group
SN  - 2330-8796
UR  - https://doi.org/10.11648/j.ajhr.20251303.11
AB  - The Factor V Leiden (G1691A), Prothrombin gene (G20210A) and MTHFR (C677T) mutations are the significant biomarkers for evaluation of tendency for venous thrombosis. The objective of our study was to assess the frequency of factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) variants in Yemeni subjects tested for thrombophilia. Methods: Our study included 441 thrombophilia subjects (138 subjects for FVL (G1691A) mutation, 164 subjects for PT (G20210A) mutation and 139 for MTHFR (C677T) mutation) who were genotyped by method of SNP Genotyping Assay (FVL, PT and MTHFR variants Real Time PCR Kits), and the allele frequencies of factor V Leiden (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations were calculated. The laboratory data of patients tested were reviewed and analyzed in the Aulaqi specialized medical laboratories. Results: Factor V Leiden (G1691A) mutation was present in 10% of all subjects (heterozygotes: 10%, homozygotes mutant: 0%). Prothrombin (G20210A) mutation was found in 8.5% of subjects (heterozygotes: 7.3%, homozygotes mutant: 1.2%) and MTHFR (C677T) mutation in 39.5% of subjects (heterozygotes: 34.5%, homozygotes mutant: 5%). Conclusion: This study reports high prevalence of FVL (G1691A), PT (G20210A) and MTHFR (C677T) mutations among subjects with thrombophilia. Consequently, genotyping assay for of the three thrombotic gene mutations have a priority in the evaluation of subjects with thrombophilia, as well as in the screening for additional clinical conditions correlated with an elevated risk of thrombosis in Sana'a city-Yemen.

VL  - 13
IS  - 3
ER  -

Copy | Download

Author Information

Mohammed Ahamed Hajar

Department of Hematology, Faculty of Medicine and Health Science, Sana'a University, Sana'a, Yemen

Contact Email

http://orcid.org/0009-0002-9812-8792
Sami Sultan Ahmed

Aulaqi Specialized Medical Laboratories, Sana'a, Yemen

Contact Email

http://orcid.org/0009-0001-2408-6027
Basem Mohammed Abdulfattah

Aulaqi Specialized Medical Laboratories, Sana'a, Yemen

Contact Email

http://orcid.org/0009-0005-4961-4016

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Hajar, M. A., Ahmed, S. S., Abdulfattah, B. M. (2025). Factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) Mutations in Yemeni Subjects Tested for Thrombophilia. American Journal of Health Research, 13(3), 131-138. https://doi.org/10.11648/j.ajhr.20251303.11

Copy | Download

ACS Style

Hajar, M. A.; Ahmed, S. S.; Abdulfattah, B. M. Factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) Mutations in Yemeni Subjects Tested for Thrombophilia. Am. J. Health Res. 2025, 13(3), 131-138. doi: 10.11648/j.ajhr.20251303.11

Copy | Download

AMA Style

Hajar MA, Ahmed SS, Abdulfattah BM. Factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) Mutations in Yemeni Subjects Tested for Thrombophilia. Am J Health Res. 2025;13(3):131-138. doi: 10.11648/j.ajhr.20251303.11

Copy | Download

@article{10.11648/j.ajhr.20251303.11,
  author = {Mohammed Ahamed Hajar and Sami Sultan Ahmed and Basem Mohammed Abdulfattah},
  title = {Factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) Mutations in Yemeni Subjects Tested for Thrombophilia
},
  journal = {American Journal of Health Research},
  volume = {13},
  number = {3},
  pages = {131-138},
  doi = {10.11648/j.ajhr.20251303.11},
  url = {https://doi.org/10.11648/j.ajhr.20251303.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajhr.20251303.11},
  abstract = {The Factor V Leiden (G1691A), Prothrombin gene (G20210A) and MTHFR (C677T) mutations are the significant biomarkers for evaluation of tendency for venous thrombosis. The objective of our study was to assess the frequency of factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) variants in Yemeni subjects tested for thrombophilia. Methods: Our study included 441 thrombophilia subjects (138 subjects for FVL (G1691A) mutation, 164 subjects for PT (G20210A) mutation and 139 for MTHFR (C677T) mutation) who were genotyped by method of SNP Genotyping Assay (FVL, PT and MTHFR variants Real Time PCR Kits), and the allele frequencies of factor V Leiden (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations were calculated. The laboratory data of patients tested were reviewed and analyzed in the Aulaqi specialized medical laboratories. Results: Factor V Leiden (G1691A) mutation was present in 10% of all subjects (heterozygotes: 10%, homozygotes mutant: 0%). Prothrombin (G20210A) mutation was found in 8.5% of subjects (heterozygotes: 7.3%, homozygotes mutant: 1.2%) and MTHFR (C677T) mutation in 39.5% of subjects (heterozygotes: 34.5%, homozygotes mutant: 5%). Conclusion: This study reports high prevalence of FVL (G1691A), PT (G20210A) and MTHFR (C677T) mutations among subjects with thrombophilia. Consequently, genotyping assay for of the three thrombotic gene mutations have a priority in the evaluation of subjects with thrombophilia, as well as in the screening for additional clinical conditions correlated with an elevated risk of thrombosis in Sana'a city-Yemen.
},
 year = {2025}
}

Copy | Download

TY  - JOUR
T1  - Factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) Mutations in Yemeni Subjects Tested for Thrombophilia

AU  - Mohammed Ahamed Hajar
AU  - Sami Sultan Ahmed
AU  - Basem Mohammed Abdulfattah
Y1  - 2025/05/24
PY  - 2025
N1  - https://doi.org/10.11648/j.ajhr.20251303.11
DO  - 10.11648/j.ajhr.20251303.11
T2  - American Journal of Health Research
JF  - American Journal of Health Research
JO  - American Journal of Health Research
SP  - 131
EP  - 138
PB  - Science Publishing Group
SN  - 2330-8796
UR  - https://doi.org/10.11648/j.ajhr.20251303.11
AB  - The Factor V Leiden (G1691A), Prothrombin gene (G20210A) and MTHFR (C677T) mutations are the significant biomarkers for evaluation of tendency for venous thrombosis. The objective of our study was to assess the frequency of factor V Leiden (G1691A), Prothrombin (G20210A) and MTHFR (C677T) variants in Yemeni subjects tested for thrombophilia. Methods: Our study included 441 thrombophilia subjects (138 subjects for FVL (G1691A) mutation, 164 subjects for PT (G20210A) mutation and 139 for MTHFR (C677T) mutation) who were genotyped by method of SNP Genotyping Assay (FVL, PT and MTHFR variants Real Time PCR Kits), and the allele frequencies of factor V Leiden (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations were calculated. The laboratory data of patients tested were reviewed and analyzed in the Aulaqi specialized medical laboratories. Results: Factor V Leiden (G1691A) mutation was present in 10% of all subjects (heterozygotes: 10%, homozygotes mutant: 0%). Prothrombin (G20210A) mutation was found in 8.5% of subjects (heterozygotes: 7.3%, homozygotes mutant: 1.2%) and MTHFR (C677T) mutation in 39.5% of subjects (heterozygotes: 34.5%, homozygotes mutant: 5%). Conclusion: This study reports high prevalence of FVL (G1691A), PT (G20210A) and MTHFR (C677T) mutations among subjects with thrombophilia. Consequently, genotyping assay for of the three thrombotic gene mutations have a priority in the evaluation of subjects with thrombophilia, as well as in the screening for additional clinical conditions correlated with an elevated risk of thrombosis in Sana'a city-Yemen.

VL  - 13
IS  - 3
ER  -

Copy | Download